TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who do have continuous contact with ill person (staff members, dormitory, family members), laboratory confirmed viral origin, during influenza/other acute viral respiratory disease season~* First exposure with the ill person who is present with symptoms of flu or acute respiratory viral infection (fever, intoxication, catarrhal symptoms) ≤ 48 hours~* Signed Informed Contest to participate in the study~* Contraception throughout the study~Exclusion Criteria:~* Interferone or interferone inducers intake, or substances with action on immune system intake less then 3 months before inclusion~* Anti-virals intake, other then investigational drug, throughout the study~* Vaccination for Influenza less than 1 year before inclusion~* Pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Ingavirin (Type: EXPERIMENTAL): Ingavirin (Imidazolyl Ethanamide Pentandioic Acid) capsules, 90 mg once daily for 7 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo oral capsule, once daily for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: HSP-glomerulonephritis Trial: MP vs CyA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* On the basis of a renal biopsy, the patient has been diagnosed for crescentic HSP glomerulonephritis of ISKDC grade III or IV or HSP glomerulonephritis of ISKDC grade II + a definite nephrotic syndrome (proteinuria \> 40 mg/m2/h).~Exclusion Criteria:~* The child is on regular medication known to interact with cyclosporine. Such medication includes cisapride, phenytoin, phenobarbital, carbamazepine, digoxin and anti-inflammatory pain medication.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must range in age from 30 to 70 years.~2. Patients must be able to communicate meaningfully with the investigator and must be legally competent to provide written informed consent.~3. Patients may be of either sex. Female patients must be non-lactating and must either be at least two years post-menopausal, or be using adequate contraceptive precautions or be surgically sterilized.~4. Patients must meet the American Diabetes Association Criteria for diagnosis of type 2 diabetes mellitus.~5. Patients must be on diet therapy alone and/or metformin treatment (stable dose) and have a fasting plasma glucose concentration between 126 and 260 mg/dl.~6. Patients must have Hematocrit greater than 34%.~7. Subjects whose body weight has been stable (±1 Kg) over the three months prior to study will be included.~Exclusion Criteria:~1, Type 1 diabetes.~2. Fasting plasma glucose greater than 260 mg/dl.~3. Patients must not have received a thiazolidinedione for at least 3 months prior to randomization.~4. Patients must not be on insulin treatment or have received insulin for more than one week within the previous year prior to entry. Patients should not be on sulfonylureas, sitagliptin, or exenatide treatment.~5. Patients taking systemic glucocorticoids or other medications known to affect glucose tolerance are excluded.~6. Patients taking medications that affect gastrointestinal motility will be excluded~7. Patients with a history of Congestive Heart failure (CHF), or clinically significant cardiac, liver or kidney disease (creatinine greater than 1.8 mg/dl).

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Pioglitazone and exenatide (Type: EXPERIMENTAL): Exenatide 10 micrograms injected subcutaneously twice daily plus pioglitazone 45 mg daily orally for 12 months.
- Pioglitazone (Type: EXPERIMENTAL): Pioglitazone 45 mg daily orally for 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Success of Tocilizumab in RA Patients With Remission Induction and Sustained Efficacy After Discontinuation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with RA in accordance with the 1987 classification criteria of ACR~* Aged 20 to 75 years inclusive at enrolment (within 2 weeks before starting treatment with the investigational drug)~* Treated with MTX at ≥6 mg/week for at least 8 weeks immediately before enrolment~* Rheumatoid arthritis of duration ≤10 years~* DAS28-ESR ≥3.2 (within 2 weeks before starting treatment with the investigational drug)~* Having received and thoroughly understood an adequate explanation about participation in the study, patients who have personally and voluntarily provided written informed consent~Major exclusion criteria:~* Patients who were Steinbrocker Class IV.~* Patients who received leflunomide within 12 weeks, DMARDs other than MTX within 8 weeks , or tacrolimus within 4 weeks before the 1st TCZ infusion.~* Patients who previously received biologic DMARDs including TCZ.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- SWITCH (Type: ACTIVE_COMPARATOR): Tocilizumab monotherapy
- ADD-ON (Type: ACTIVE_COMPARATOR): Tocilizumab plus methotrexate combination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Study of 5 and 10 mg Corplex™ Donepezil TDS Compared to 10 mg Aricept® in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy males and females.~* Subject's Body Mass Index (BMI) must be between 18 and 32 kg/m2 (inclusive).~* Subject must be continuous non-smokers.~* Subject must have a Fitzpatrick skin type of I, II or III.~Exclusion Criteria:~* History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the subject or the validity of the study results.~* After resting seated for at least 3 minutes, subjects should be excluded from the study with the following vital signs at Screening~  1. systolic blood pressure outside the range of 90-145 mmHg, or~ 2. diastolic blood pressure outside the range of 50-90 mmHg, or~ 3. resting heart rate outside the range of 40-100 beats per minute.~* Has an isolated ALT ≥1.5x the ULN or AST ≥1.5x the ULN at Screening; or both ALT and AST exceeding the ULN.~* Estimated creatinine clearance at screening \<70 mL/min/1.73 m2.~* Prolonged corrected QT (Fridericia) on screening ECG (≥450 ms for both females and males).~* History or presence of excessive hairy skin on application sites as deemed by the Investigator to potentially interfere with patch adhesion or drug absorption.~* History or presence of significant skin damage, diffuse skin diseases-, scars, tattoos on the application sites or other skin disturbances as deemed by the Investigator to potentially interfere with drug absorption or skin tolerability assessments~* Use of donepezil hydrochloride or related drugs within 60 days prior to the first study drug administration.~* Has participated in another clinical trial within 30 days prior to Day -1.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Treatment A (Type: EXPERIMENTAL): 5 mg/day Donepezil Transdermal Delivery System (TDS) 1-week wear and applied weekly for 5 consecutive weeks
- Treatment B (Type: EXPERIMENTAL): 10 mg/day Donepezil TDS 1-week wear and applied weekly for 5 consecutive weeks
- Treatment C (Type: ACTIVE_COMPARATOR): 10 mg/day Aricept® donepezil tablet administered QD for 5 consecutive weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects 6 to 11 years of age, as of the Screening Visit (SV)~* A documented history of SAR to a relevant seasonal allergen (tree/grass pollen) for a minimum of two years immediately preceding the study Screening Visit (SV).~* A demonstrated sensitivity to at least one seasonal allergen (tree/grass pollen) known to induce SAR through a standard skin prick test.~* Other criteria apply~Exclusion Criteria:~* History of physical findings of nasal pathology, including nasal polyps or other clinically significant respiratory tract malformations, recent nasal biopsy, nasal trauma (e.g., nasal piercing) or surgery, atrophic rhinitis, or rhinitis medicamentosa (all within the last 60 days prior to the Screening Visit \[SV\])~* History of a respiratory infection or disorder (including, but not limited to bronchitis, pneumonia, chronic sinusitis or influenza,) within the 14 days preceding the Screening Visit (SV), or development of a respiratory infection during the Run-in Period.~* Active asthma requiring treatment with inhaled or systemic corticosteroids and/or routine use of beta-agonists and any controller drug (e.g., theophylline, leukotriene antagonists). History of intermittent use (less than or equal to 3 uses per week) of inhaled short acting beta-agonists prior to the Screening Visit (SV) is acceptable~* Have any conditions that are judged by the investigator to be clinically significant and/or affect the subject's ability to participate in the clinical trial~* Other criteria apply

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- BDP HFA 80 mcg/day (Type: EXPERIMENTAL): Participants/parents administer 40 mcg of beclomethasone dipropionate hydrofluoroalkane (BDP HFA) (one spray per nostril) once daily for 15 days.
- BDP HFA 160 mcg/day (Type: EXPERIMENTAL): Participants/parents administer 80 mcg of beclomethasone dipropionate hydrofluoroalkane (BDP HFA) (one spray per nostril) once daily for 15 days.
- Placebo nasal aerosol once daily (Type: PLACEBO_COMPARATOR): Participants/parents administer placebo (a spray with no medication in each nostril) once daily for 15 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Iloperidone in Mixed States of Bipolar Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female;~2. Age 18 years and older~3. Patients on:~   * Li at a stable dose for 2 weeks or longer, and a serum level at screening of greater than or equal to 0.5 mEq/l OR~  * DIV dose for 2 weeks or longer, and a serum level at screening of greater than or equal to 45 ug/ml OR~  * LAM (dosage/day ≥100mg) at a stable dose for 2 weeks or longer OR~  * Any combination 3a, 3b, or 3c~4. Patients meeting DSM-IV TR diagnosis of bipolar disorder, I or II, as assessed using the MINI, (Sheehan et al., 1998) PLUS any ONE of criteria 5 or 6 or 7~5. Patients meeting DSM-IV TR diagnostic criteria for a mixed manic episode with Young Mania Rating Scale (YMRS) score\>/=14 and Montgomery Asberg Depression Rating Scale (MADRS) score\>/=14~6. Patients meeting the criteria for a manic/hypomanic episode for at least 2 days with the simultaneous presence of Young Mania Rating Scale (YMRS) score\>/=14 PLUS Montgomery Asberg Depression Rating Scale (MADRS) score\>/=14 ;~7. Patients meeting DSM-IV TR diagnostic criteria for a major depressive episode with the simultaneous presence of MADRS score\>/=14 PLUS meeting the criteria for a manic/hypomanic episode for at least 2 days with the simultaneous presence of Young Mania Rating Scale (YMRS) score\>/=14~Exclusion Criteria:~1. Patients with a current Axis I diagnosis of schizophrenia, schizophreniform disorder, schizotypal disorder, bipolar disorder with psychotic sub-type that requires hospitalization, drug induced mania or AIDS induced mania~2. Women with a positive pregnancy test or who are lactating~3. Women of child-bearing potential who are not practicing a clinically accepted method of contraception~4. Patients with general medical conditions that contraindicate psychoactive medications or uncontrolled medical disorder or central nervous system diseases.~5. Patients whose clinical status requires inpatient or day hospital treatment~6. History of severe side effects associated with therapeutic doses of Li, DIV, LAM~7. Alcohol or drug dependent at time of enrollment~8. Suicidal at time of enrollment.~9. Current or previous exposure to iloperidone~10. Patients taking medication that cause QTC prolongation~11. Patients with serious cardiac disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open Label iloperidone (Type: EXPERIMENTAL): open label iloperidone (oral tablet, 6mg-24mg, QD, 20 weeks) as adjunct to current lithium, divalproex, or lamotrigine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Add-on to Thiazolidinedione (TZD) Failures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females, ≥ 18 years old, with type 2 diabetes and with inadequate glycemic control~* All subjects must have central laboratory pre-randomization A1C ≥ 7.0 and ≤ 10.5%~* C-peptide ≥ 1.0 ng/mL (0.34 nmol/L)~* Body Mass Index ≤ 45.0 kg/m²~Exclusion Criteria:~* AST and /or ALT \> 2.5 times the upper limit of normal~* Serum total bilirubin \> 2 mg/dL (34.2 µmol/L)~* Creatinine kinase \> 3.0 times the upper limit of normal~* Symptoms of severely uncontrolled diabetes~* Serum creatinine ≥ 2.0 mg/dL~* Calculated Cr-Clearance \< 50 ml/min (calculated by Cockroft-Gault formula)~* Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: EXPERIMENTAL): None
- Arm 3 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study on How Fiasp® Can Influence Blood Sugar Levels of type1 Diabetic Patients in Their Daily Lives, With the Help of the Freestyle Libre® Device

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signed consent obtained before any study-related activities (study-related activities are any procedures related to recording of data according to protocol)~* The decision to initiate treatment with commercially available Fiasp® has been made by the patient and the treating physician before and independently from the decision to include the patient in this study~* Male or female, age greater than or equal to 18 years at the time of signing informed consent~* Diagnosed with T1DM at least 1 year prior to inclusion in the study~* Stable treatment by MDI/CSII for at least 6 months prior to inclusion in the study. Stable treatment is defined as not changing the treatment method, with dose adjustments allowed~* Regular (defined as usage on a monthly basis) user of Freestyle Libre® flash glucose monitoring for at least 6 months as the only continuous glucose monitoring (CGM) system actively used and availability of a full 2 weeks sensor download as csv file with 80% completeness of the data (if more sensor data are available, the 2 week data closest to baseline visit will be used)~* Latest HbA1c value measured in the 3 months prior to inclusion in the study between 7.5-9.5%~Exclusion Criteria:~* Previous participation in this study. Participation is defined as having given informed consent in this study~* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation~* Anti-diabetic treatment intensification during the last 3 months prior to inclusion in the study. Treatment intensification is defined as adding new anti-diabetic medication to previous treatment regimen~* Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive methods. Only highly effective methods of birth control are accepted (i.e. one that results in less than 1% per year failure rate when used consistently and correctly such as implants, injectables, combined oral contraceptives, certain intrauterine devices), or sexual abstinence or a vasectomised partner

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fast-acting insulin aspart (Type: None): Participants will receive fast-acting insulin aspart at the treating physician's discretion as part of the usual clinical practice. The prescription and use of fast-acting insulin aspart is completely independent of this study. Total study duration for the individual patient will be approximately 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Iloprost Effects on Gas Exchange and Pulmonary Mechanics

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Pulmonary hypertension as evidenced by:~   * In patients with a pulmonary artery catheter, a mean pulmonary arterial pressure greater then 25 mmHg with a pulmonary capillary wedge pressure less than or equal to 15 mmHg, or~  * Echocardiographic evidence of pulmonary arterial hypertension including~     * a PA systolic pressure greater than 35 mmHg, or~    * in those patients in whom a PA systolic cannot be estimated for technical reasons, RV dilatation and/or decreased RV function in the presence of normal LV function.~2. ARDS/ALI as indicated by:~   * Diffuse pulmonary infiltrates involving at least three of four quadrants on chest x-ray.~  * PaO2/FIO2 less than 300 while on mechanical ventilation.~  * Recognized cause of ARDS/ALI~  * Absence of clinical evidence of left atrial hypertension~3. presence of an arterial line for pressure monitoring and blood sampling, and~4. the ability to obtain informed consent from the patient or next of kin.~Exclusion Criteria:~1. clinical instability as evidenced by changes in ventilator settings or medications within the preceding hour, and~2. presence of left ventricular dysfunction and/or left atrial enlargement by cardiac echo, or catheterization,~3. Liver failure (Child-Pugh Class B or C)~4. Renal failure on dialysis~5. Pregnancy: all females of child-bearing potential will have a negative pregnancy test before being allowed to enroll~6. Systolic blood pressure less than 85 mm Hg or the need for pressors in the first 10 patients; after review of the first 10 patients by the DMSB, patients on norepinephrine (without additional pressors) in doses less than 0.2 mcg/kg/min may be enrolled if the DMSB finds no evidence of iloprost induced systemic hypotension in the first 10 patients~7. Thrombocytopenia, bleeding diathesis or active bleeding~8. Asthma/Severe bronchospasm~9. Age \< 18 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Iloprost (Type: EXPERIMENTAL): All patients will have their response to Iloprost compared to baseline pre-treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: On Demand Contraception: Ulipristal Acetate Plus a COX-2 Inhibitor at Peak Fertility

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Women, aged 18-38~* English speaking~* Able to consent, literate~* Access to smart phone throughout study~* History of regular menses~* Documented baseline cycle with ovulation~* Not currently using or needing hormonal contraception~* Not currently using or needing regular NSAIDS~* Able to commit to frequency of study visits~Exclusion Criteria:~* Currently or recently (\<2months) pregnant~* Currently or recent (\<2months) breastfeeding~* Current or recent (\<2months) use of hormonal medication~* Regular NSAID use~* Known cardiac risk factors (e.g. personal history of obesity, HTN, cardiac disease, diabetes)~* BMI \> 30, as some studies have shown decreased efficacy of ulipristal in obese women37~* Allergy or previous unacceptable side effects with study medications

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 38 Years
- Healthy Volunteers: t

Study Arms:
- Ulipristal 30mg plus Meloxicam 15mg (Type: EXPERIMENTAL): Each study participant will complete one menstrual cycle without medication. Her second menstrual cycle, each study participant will receive ulipristal acetate plus meloxicam at peak fertility.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete